SCHEMBL13229697

SCHEMBL13229697

CC(=O)c1c[nH]c2ccsc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.49
HTR3A P46098 1/20 0.49
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 1/20 0.49
PBRM1 Q86U86 1/20 0.45
ALDH1A1 P00352 4/20 0.41
TP53 P04637 2/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
HASPIN Q8TF76 1/20 0.35
BRPF1 P55201 1/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
PDPK1 O15530 2/20 0.34
PARP1 P09874 1/20 0.34
CFTR P13569 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2793777 0.85 CYP3A4 (0.50) CYP3A4HTR3AHSD17B10KDM4EALDH1A1
SCHEMBL6708336 0.83 CYP3A4 (0.49) CYP3A4HTR3AHSD17B10KDM4EALDH1A1
SCHEMBL13229581 0.83 CYP3A4 (0.55) CYP3A4HTR3AKDM4EALDH1A1TP53
SCHEMBL10472393 0.80 GABRA1 (0.52) CYP3A4HTR3AHTR2AHTR2CHTR2B
SCHEMBL13229587 0.78 CFTR (0.63) CYP3A4HTR3AHSD17B10KDM4EALDH1A1
SCHEMBL31549260 0.75 F7 (0.43) CYP3A4HTR3AHSD17B10KDM4EALDH1A1
SCHEMBL13229624 0.74 CFTR (0.48) CYP3A4HTR3AHSD17B10KDM4EALDH1A1
SCHEMBL13229620 0.74 CYP3A4 (0.47) CYP3A4HTR3AALDH1A1TP53CFTR
SCHEMBL15562633 0.74 ALDH1A1 (0.49) CYP3A4HTR3AHSD17B10ALDH1A1MEN1
SCHEMBL23937804 0.73 CYP3A4 (0.43) CYP3A4HTR3AKDM4EPBRM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140235668-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-21 US disclosed
US-20130231364-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-05 US disclosed
US-8399479-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-03-19 US disclosed
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235668-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI CFTR, ABCB1, ABCC1 CYP3A4 3757/4885HTR3A 4289/4885HSD17B10 2762/4885
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC1 CYP3A4 3621/4885HTR3A 3751/4885HSD17B10 1895/4885
US-20130231364-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC1 CYP3A4 3621/4885HTR3A 3751/4885HSD17B10 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.